Financial updates
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
Jupiter, FL – [August 19, 2025] – Myosin Therapeutics, a biotechnology company developing novel therapies...
Financial updates
Myosin Therapeutics Awarded $3 Million NIH Grant to Advance Clinical Trial for MT-110 in Methamphetamine Use Disorder
Jupiter, FL – Apr 28, 2025, 14:00 ET – Myosin Therapeutics, Inc., a biotechnology company...
Financial updates
Myosin Therapeutics Closes Second Seed Round to Advance Clinical Trials for Innovative Cancer and Neuroscience Therapies
JUPITER, Fla., Feb. 26, 2025 /PRNewswire/ — Myosin Therapeutics, Inc., a biotechnology company developing novel...
Financial updates
Myosin Therapeutics Successfully Transitions to Second Phase of NCI’s Fast Track Funding to Advance MT-125
Jupiter, FL – [January 16, 2024] – After milestone review by the NIH’s National Cancer...
Financial updates
Myosin Therapeutics Closes Seed Round to Continue Development of Innovative Therapies for Glioblastoma and Stimulant Use Disorder
Jupiter, FL – [March 7th, 2023] – Myosin Therapeutics Inc., a biotechnology company leveraging its...
